Vaccines Against Invasive Salmonella Disease: Current Status and Future Directions

Overview

Journal Hum Vaccin Immunother

Specialty Allergy & Immunology

Date 2014 May 9

PMID 24804797

Citations 114

Authors

Calman A MacLennan

Laura B Martin

Francesca Micoli

Affiliations

Soon will be listed here.

Abstract

Though primarily enteric pathogens, Salmonellae are responsible for a considerable yet under-appreciated global burden of invasive disease. In South and South-East Asia, this manifests as enteric fever caused by serovars Typhi and Paratyphi A. In sub-Saharan Africa, a similar disease burden results from invasive nontyphoidal Salmonellae, principally serovars Typhimurium and Enteritidis. The existing Ty21a live-attenuated and Vi capsular polysaccharide vaccines target S. Typhi and are not effective in young children where the burden of invasive Salmonella disease is highest. After years of lack of investment in new Salmonella vaccines, recent times have seen increased interest in the area led by emerging-market manufacturers, global health vaccine institutes and academic partners. New glycoconjugate vaccines against S. Typhi are becoming available with similar vaccines against other invasive serovars in development. With other new vaccines under investigation, including live-attenuated, protein-based and GMMA vaccines, now is an exciting time for the Salmonella vaccine field.

Citing Articles

SHASI-ML: a machine learning-based approach for immunogenicity prediction in vaccine development.

Spiga O, Visibelli A, Pettini F, Roncaglia B, Santucci A Front Cell Infect Microbiol. 2025; 15:1536156.

PMID: 40007603 PMC: 11850321. DOI: 10.3389/fcimb.2025.1536156.

Foodborne Infections and : Current Primary Prevention Tools and Future Perspectives.

Zizza A, Fallucca A, Guido M, Restivo V, Roveta M, Trucchi C Vaccines (Basel). 2025; 13(1).

PMID: 39852807 PMC: 11768952. DOI: 10.3390/vaccines13010029.

Salmonella Typhimurium derived OMV nanoparticle displaying mixed heterologous O-antigens confers immunogenicity and protection against STEC infections in mice.

Bian X, Chen Y, Zhang W, Liu X, Lei M, Yuan H Microb Cell Fact. 2025; 24(1):8.

PMID: 39773741 PMC: 11705740. DOI: 10.1186/s12934-024-02640-6.

Phage-resistance alters Lipid A reactogenicity: a new strategy for LPS-based conjugate vaccines against Rissen.

Cuomo P, Medaglia C, Casillo A, Gentile A, Fruggiero C, Corsaro M Front Immunol. 2024; 15:1450600.

PMID: 39723217 PMC: 11668645. DOI: 10.3389/fimmu.2024.1450600.

Immunogenicity and cross-protective efficacy induced by delayed attenuated with regulated length of lipopolysaccharide in mice.

Bian X, Liu Q, Chen Y, Zhang W, Li M, Zhang X Gut Microbes. 2024; 16(1):2424983.

PMID: 39529227 PMC: 11559367. DOI: 10.1080/19490976.2024.2424983.

References

McSorley S, Jenkins M . Antibody is required for protection against virulent but not attenuated Salmonella enterica serovar typhimurium. Infect Immun. 2000; 68(6):3344-8. PMC: 97596. DOI: 10.1128/IAI.68.6.3344-3348.2000. View

Levine M, Ferreccio C, Cryz S, Ortiz E . Comparison of enteric-coated capsules and liquid formulation of Ty21a typhoid vaccine in randomised controlled field trial. Lancet. 1990; 336(8720):891-4. DOI: 10.1016/0140-6736(90)92266-k. View

Breiman R, Cosmas L, Njuguna H, Audi A, Olack B, Ochieng J . Population-based incidence of typhoid fever in an urban informal settlement and a rural area in Kenya: implications for typhoid vaccine use in Africa. PLoS One. 2012; 7(1):e29119. PMC: 3261857. DOI: 10.1371/journal.pone.0029119. View

Raffatellu M, Santos R, Verhoeven D, George M, Wilson R, Winter S . Simian immunodeficiency virus-induced mucosal interleukin-17 deficiency promotes Salmonella dissemination from the gut. Nat Med. 2008; 14(4):421-8. PMC: 2901863. DOI: 10.1038/nm1743. View

Rondini S, Lanzilao L, Necchi F, OShaughnessy C, Micoli F, Saul A . Invasive African Salmonella Typhimurium induces bactericidal antibodies against O-antigens. Microb Pathog. 2013; 63:19-23. DOI: 10.1016/j.micpath.2013.05.014. View

Gil-Cruz C, Bobat S, Marshall J, Kingsley R, Ross E, Henderson I . The porin OmpD from nontyphoidal Salmonella is a key target for a protective B1b cell antibody response. Proc Natl Acad Sci U S A. 2009; 106(24):9803-8. PMC: 2701014. DOI: 10.1073/pnas.0812431106. View

MacLennan C, Gondwe E, Msefula C, Kingsley R, Thomson N, White S . The neglected role of antibody in protection against bacteremia caused by nontyphoidal strains of Salmonella in African children. J Clin Invest. 2008; 118(4):1553-62. PMC: 2268878. DOI: 10.1172/JCI33998. View

Roumagnac P, Weill F, Dolecek C, Baker S, Brisse S, Chinh N . Evolutionary history of Salmonella typhi. Science. 2006; 314(5803):1301-4. PMC: 2652035. DOI: 10.1126/science.1134933. View

Trebicka E, Jacob S, Pirzai W, Hurley B, Cherayil B . Role of antilipopolysaccharide antibodies in serum bactericidal activity against Salmonella enterica serovar Typhimurium in healthy adults and children in the United States. Clin Vaccine Immunol. 2013; 20(10):1491-8. PMC: 3807195. DOI: 10.1128/CVI.00289-13. View

10.

Gordon M, Gordon S, Musaya L, Zijlstra E, Molyneux M, Read R . Primary macrophages from HIV-infected adults show dysregulated cytokine responses to Salmonella, but normal internalization and killing. AIDS. 2007; 21(18):2399-408. DOI: 10.1097/QAD.0b013e3282f25107. View

11.

Engels E, Falagas M, Lau J, Bennish M . Typhoid fever vaccines: a meta-analysis of studies on efficacy and toxicity. BMJ. 1998; 316(7125):110-6. PMC: 2665386. DOI: 10.1136/bmj.316.7125.110. View

12.

Gordon M, Graham S, Walsh A, Wilson L, Phiri A, Molyneux E . Epidemics of invasive Salmonella enterica serovar enteritidis and S. enterica Serovar typhimurium infection associated with multidrug resistance among adults and children in Malawi. Clin Infect Dis. 2008; 46(7):963-9. DOI: 10.1086/529146. View

13.

Sinha K, Mastroeni P, Harrison J, de Hormaeche R, Hormaeche C . Salmonella typhimurium aroA, htrA, and aroD htrA mutants cause progressive infections in athymic (nu/nu) BALB/c mice. Infect Immun. 1997; 65(4):1566-9. PMC: 175172. DOI: 10.1128/iai.65.4.1566-1569.1997. View

14.

Ali A, An S, Cui C, Haque A, Carbis R . Preparation and evaluation of immunogenic conjugates of Salmonella enterica serovar Typhi O-specific polysaccharides with diphtheria toxoid. Hum Vaccin Immunother. 2012; 8(2):189-93. DOI: 10.4161/hv.18350. View

15.

Poolman J, Borrow R . Hyporesponsiveness and its clinical implications after vaccination with polysaccharide or glycoconjugate vaccines. Expert Rev Vaccines. 2011; 10(3):307-22. DOI: 10.1586/erv.11.8. View

16.

Levine M, Ferreccio C, Abrego P, Martin O, Ortiz E, Cryz S . Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine. Vaccine. 1999; 17 Suppl 2:S22-7. DOI: 10.1016/s0264-410x(99)00231-5. View

17.

Szu S . Development of Vi conjugate - a new generation of typhoid vaccine. Expert Rev Vaccines. 2013; 12(11):1273-86. DOI: 10.1586/14760584.2013.845529. View

18.

Germanier R, Fuer E . Isolation and characterization of Gal E mutant Ty 21a of Salmonella typhi: a candidate strain for a live, oral typhoid vaccine. J Infect Dis. 1975; 131(5):553-8. DOI: 10.1093/infdis/131.5.553. View

19.

MacLennan C, Tennant S . Comparing the roles of antibodies to nontyphoidal Salmonella enterica in high- and low-income countries and implications for vaccine development. Clin Vaccine Immunol. 2013; 20(10):1487-90. PMC: 3807204. DOI: 10.1128/CVI.00465-13. View

20.

Ochiai R, Wang X, von Seidlein L, Yang J, Bhutta Z, Bhattacharya S . Salmonella paratyphi A rates, Asia. Emerg Infect Dis. 2005; 11(11):1764-6. PMC: 3367370. DOI: 10.3201/eid1111.050168. View